Tamoxifen

Chemical name

(Z)-2-[4-(1,2-Дифенил-1-буте��ил)фенокси]-N,N-диметил этанамин (in the form of citrate)

Gross

C26-H29-N-O

Of drugs

The drugs-protivoopujolevoe, antiestrogennoe. Competitive contact estrogenovmi receptors in organah-misheniah like oestrogens transloziruetsa together with the receptor in the nucleus of neoplastic cells and blocks the effect of estrogen.

Indications

Breast cancer, especially for women in menopause endometrium cancer, kidney sarcoma of soft tissues, anovulatornoe infertility, oligospermia, pituitary tumors.

Restrictions on the use of

Lakopenia, thrombocytopenia, gipercalziemia.

Contraindications

Pregnancy, bophlebitis.

Side-Effects

Gastrointestinal disorders (anorexia, nausea, vomiting), dizziness, skin rashes, gipercalziemia, thrombocytopenia, moderate metrorragia, labor, it is very rarely the body temperature, it is rarely produced horn envelope retinal degeneration.

Specific guidance

Few effective in the treatment of patients with cancer (especially the liver).

Patient interaction

Cytostatics increase the risk tromboobrazovania. Can be used successfully in combination with progestinami.

Precautions

In the treatment needed to be monitored in cells, platelets, the level of calcium, indicators of blood coagulation.

Dosing and Administration

Inside, and breast cancer, endometrium, kidney, on 10-20 mg 2-3 times a day for a course-2,4-9,6 g; A treatment until signs of regression process, and in the next 1-2 months. In anovulatornom barrenness appoint 10 mg twice a day for four days, starting with two days of menstruation, the dose could be increased to 20 mg and then 40 mg. In the event of termination of milk after childbirth, and 10 mg four times a day for 5 days. In oligospermii-to 10 mg twice a day.

Directory → Antineoplastic funds → Antineoplastic hormonal and hormone antagonists → Tamoxifen